Search the Newsreel

Top Midday Gainers

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The committee voted 10 to 3 that the efficacy Silver Upgrade …

Replimune rebounds as positive AdCom vote prompts Cantor upgrade

[Wall Street New York stock exchange stock market] alexsl Despite a multi-day decline earlier this week, Replimune (REPL [https://seekingalpha.com/symbol/REPL]) shares bounced back on Friday as Cantor Fitzgerald upgraded the biotech after an FDA advisory committee voted in favor of the company’s lead, RP1, targeted …

Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G

Vanguard Capital Management has disclosed a 5% beneficial ownership stake in Repligen Corp (RGEN) through a Schedule 13G filing. This represents 2,825,579 shares of common stock, with Vanguard holding sole voting power over 414,408 shares and sole dispositive power over all 2,825,579 shares. The …

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote

Replimune Group's shares more than doubled after a positive FDA advisory committee vote on its IGNYTE study data for RP1 in combination with nivolumab for advanced melanoma. The committee voted 10 to 3 that the study results are clinically meaningful and evaluable, despite previous …

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote

An FDA advisory panel voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, increasing its chances of approval despite two prior rejections and concerns from FDA scientists about the trial data. The decision comes ahead of an August 2 deadline for the FDA …

Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more

Check out the companies making the biggest moves premarket: Replimune Group — Shares were up over 130% for the clinical-stage biotechnology company after a Food and Drug Administration advisory panel voted in favor of the company's RP1 drug trial results for a type of …

Replimune stock upgraded at Cantor on FDA vote (REPL:NASDAQ)

Replimune (REPL) shares rebounded following an upgrade by Cantor Fitzgerald. The upgrade came after an FDA advisory committee voted favorably for the company's lead drug, RP1, which targets melanoma. This positive development occurred despite a prior multi-day decline in the stock earlier in the …

REPL Stock Jumps As FDA Panel Backs Melanoma Drug

Replimune Group Inc. (REPL) stock jumped significantly after an FDA advisory panel voted 10-3 in favor of the efficacy data for its melanoma therapy, RP1 plus nivolumab, from the IGNYTE trial. This positive recommendation de-risks the company's ongoing Biologics License Application (BLA) resubmission ahead …

Replimune stock surges on positive AdCom vote (REPL:NASDAQ)

Replimune's stock more than doubled in post-market trading after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted favorably on the company's lead asset, RP1. This positive AdCom vote precedes a key target date of August 2. The significant surge indicates strong investor …

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

An FDA advisory panel voted 10-3 in favor of Replimune Group's experimental melanoma therapy, despite regulators' earlier concerns about the trial design and data. This recommendation follows a contentious meeting and a significant drop in Replimune's stock price after a critical FDA analysis. The …

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's meeting of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies …

Bragar Eagel & Squire, P.C. is Investigating Replimune

Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Replimune Group Inc. following a significant stock drop. The investigation comes after the FDA deemed Replimune's single-arm mid-stage study for its drug RP1 for skin cancer as "not interpretable," …

Repligen (RGEN) Stock Faces A Margin Puzzle After Revenue Growth

Repligen (RGEN) recently reported Q2 2026 earnings with revenue growth and expanded adjusted gross and operating margins, despite a slip in net income. The article discusses the bull and bear cases for the stock, focusing on the company's shift towards recurring revenue and its …

Replimune’s RP-1 for melanoma wins over FDA adcom

Replimune Group Inc.'s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma, refractory to PD-1 therapy, received a positive vote from the U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The committee voted 10-3 that the efficacy results from the Ignyte phase II study …

Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL)

Replimune Group, Inc. has been downgraded to 'Sell' due to ongoing FDA concerns regarding its RP1 + OPDIVO combination for advanced melanoma. The FDA's briefing documents highlight issues with the reliance on the single-arm IGNYTE trial, lack of a control arm, and a questionable …

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

Repligen (RGEN) closed the last trading session at $141.23, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

Replimune Faces FDA Panel on RP1 Melanoma Therapy

Replimune will present data for its RP1 plus nivolumab therapy for advanced melanoma to an FDA advisory panel. The company is seeking accelerated approval for RP1, citing positive outcomes from the IGNYTE trial and previous FDA feedback, arguing its efficacy and safety profile justify …

Replimune Seeks FDA Advisory Committee Backing for RP1 + nivolumab; IGNYTE ORR 33.6% & DOR 24.8 mos

Replimune

Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup

Repligen (NASDAQ:RGEN) is highlighted as a compelling stock due to its strong fundamental growth, including significant revenue and EPS increases, combined with a promising technical breakout setup. The company shows an impressive growth rating with accelerating EPS expectations, despite an elevated valuation. Technically, RGEN …

Replimune Group (REPL) Projected to Announce Quarterly Earnings on Thursday

Replimune Group Number of Employees 2026 | Employee Count & Headcount Data

Replimune Group, a Pharmaceuticals company founded in 2015 and headquartered in Woburn, Massachusetts, had approximately 469 employees worldwide as of March 2026, representing a 35.9% growth from 2023 but a 1.2% decline year-over-year. The company's workforce is concentrated in the United States, followed by …

Repligen Corp Q2 2026: Revenue $204.1M, EPS $0.09— 10-Q Summary

Repligen Corp (RGEN) reported its second-quarter 2026 results, with revenue increasing by 11.9% year-over-year to $204.1 million. Despite the revenue growth, net income declined to $5 million, and diluted earnings per share fell to $0.09 from $0.26 in the prior-year quarter. The company also …

REPL: Replimune Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides a current overview of Replimune Group Inc. (REPL) stock, including its latest price, market performance, and financial fundamentals. It highlights recent news regarding a significant stock drop due to FDA documents and ongoing securities fraud investigations, alongside details on upcoming earnings …

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company and/or members of its senior management may have violated …

BioLife $1.5B buyout to expand Repligen Corporation (NASDAQ: RGEN) platform

Repligen Corporation reported strong Q2 2026 revenue of $204.1 million, an 11.9% increase from Q2 2025, with first-half revenue reaching $398.4 million. The company announced a definitive agreement to acquire BioLife Solutions for approximately $1.5 billion, aiming to expand its cell therapy capabilities. This …

Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up

Repligen (RGEN) reported strong second-quarter 202

Why Repligen (RGEN) Stock Is Up Today

Shares of Repligen Corporation (NASDAQ: RGEN) rose significantly after the biopharma manufacturing company reported strong second-quarter results, beating analyst expectations for both adjusted earnings and revenue. The company also raised its full-year guidance, signaling confidence in its continued performance. This positive news contrasts with …

Repligen Earnings: Excellent Profit Margins, China Recovery Underway

Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier

Repligen is highlighted as a leading provider of bioprocessing solutions for biologic drug manufacturers. The company offers a range of advanced systems including filtration, fluid management, chromatography columns, and process analytics. Despite its relatively small size, Repligen is noted for its innovation and record …

Canaccord reiterates Hold on Repligen stock, keeps $145 target

Canaccord Genuity has reiterated a Hold rating on Repligen Corp. (NASDAQ:RGEN) and maintained its $145 price target, believing the shares are fairly valued. The bioprocessing company exceeded analyst expectations for its second-quarter 2026 results, reporting strong revenue growth across all franchises and raising its …

Replimune Group, Inc. SEC Filing (Jul 28, 2026)

This article announces an SEC filing (type ARS) by Replimune Group, Inc. (REPL) on July 28, 2026. The filing was accepted by the SEC on July 28, 2026, at 06:26 PM and is available as a PDF document. StockTitan provides additional context, including filing …

Replimune tanks on FDA concerns about its skin cancer therapy

Replimune Group Inc. (NASDAQ: REPL) saw its stock slide by over 37% after the FDA released documents raising serious questions about its skin cancer treatment, RP1, ahead of an advisory committee meeting. The FDA deemed the data package "not interpretable" due to the single-arm …

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Corporation reported strong second-quarter 2026 financial results, with revenue reaching $204 million, marking a 12% year-over-year increase. The company also announced a definitive agreement to acquire BioLife Solutions, aiming to enhance its cell therapy leadership. Following these positive outcomes, Repligen raised its full-year …

Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock.

The biotech is seeking approval for its first commercial product in combination with Bristol Myers Squibb’s Opdivo. Continue Reading

Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz has initiated a securities fraud investigation into Replimune Group Inc. (REPL) after the FDA deemed the company's mid-stage study for its skin cancer drug RP1 "not interpretable." This FDA assessment caused Replimune's stock price to fall by …

FDA staff reiterate concerns about Replimune skin cancer treatment

The FDA has again expressed concerns regarding Replimune's investigational skin cancer treatment, RP1, ahead of an advisory committee meeting. Regulators cite insufficient data to support approval, specifically questioning the reliance on a single-arm trial that combines RP1 with Opdivo in patients who have failed …